News

2 Growth Stocks to Stash and 1 We Question
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...
Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.
M&A Is Back. These Stocks Could Be Targets.
Dealmaking is in style again under President Donald Trump. Potential takeover targets include C3.ai, Viking Therapeutics, and ...
Huntington Ingalls Industries Inc (HII) Q2 2025 Earnings Call Highlights: Strong Contract Wins ...
Huntington Ingalls Industries Inc (HII) reports a 3.5% revenue increase and significant contract awards, while navigating ...
Antero Resources signals lower 2026 free cash flow breakeven at $1.75 amid capital efficiency gains
Antero updated its full-year NGL price guidance slightly downward, attributing the revision to Q2 actuals impacted by inventory adjustments, but continues to expect premiums in the second half of the ...
Teleperformance shares sink 16% on outlook cut, margin miss and weak services unit
Investing.com -- Teleperformance (EPA: TEPRF) shares plunged more than 16% on Friday after the company cut its full-year revenue outlook, reported weaker-than-expected margins and missed earnings ...
Chemical Licensing Market is Projected with a Value of USD 22.74 Billion by 2032, Driven by Expanding Petrochemical Demand | Report by SNS Insider
Rising demand for energy-efficient processes and stricter emission norms are boosting global adoption of licensed chemical technologies and innovations.Austin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The ...